A naukri.com initiative
Bioengineer
3d
229
Image Credit: Bioengineer
Reprogramming Cancer Cells: A Breakthrough Approach to Treat Aggressive Leukemia
- A collaborative study by Ludwig Cancer Research introduces a novel combination therapy for acute myelogenous leukemia (AML) that targets the differentiation blockade inherent in the disease.
- The therapy aims to activate gene expression programs promoting cellular differentiation while suppressing those contributing to uncontrolled proliferation, with a focus on epigenetic regulators like LSD1.
- By combining LSD1 inhibition with a GSK3α/β inhibitor, the study showed promising results in inducing differentiation and halting proliferation across various AML subtypes in vitro and in vivo models.
- The drug combination selectively targeted leukemic cells, extending survival in animal models while sparing normal hematopoietic stem cells, suggesting a favorable therapeutic index.
- Molecular analyses revealed that the therapy reprogrammed gene expression networks, mitigated WNT signaling overactivation, and aligned with prolonged survival signatures in AML patients.
- Clinical trials for the combination therapy, leveraging existing clinical evaluation of LSD1 and GSK3 inhibitors, are forthcoming to assess safety and efficacy in humans.
- The study's holistic approach, combining epigenetic modulation with pharmacology, offers hope for transforming AML into a manageable or curable disease with improved quality of life for patients.
- Supported by various organizations, the research exemplifies international collaboration and funding synergies in advancing cancer therapeutics and marks a significant step forward in the global fight against cancer.
- The study's interdisciplinary nature, led by Professor Yang Shi of Ludwig Oxford, underscores the potential of innovative ideas in cancer therapeutics to swiftly benefit patients worldwide.
- The research provides a beacon of hope for redefining AML treatment standards and inspiring novel strategies against other epigenetically driven cancers through integrative science and translational research.
Read Full Article
13 Likes
For uninterrupted reading, download the app